scholarly journals A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)

2017 ◽  
Vol 64 (11) ◽  
pp. e26565 ◽  
Author(s):  
James I. Geller ◽  
John P. Perentesis ◽  
Xiaowei Liu ◽  
Charles G. Minard ◽  
Rachel A. Kudgus ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Phase 1 ◽  
Study Phase ◽  
Oncology Group ◽  
Phase 1 Study ◽  
Oncology Group Study ◽  
Met Inhibitor

A phase 1 study of the c-Met inhibitor tivantinib (ARQ 197, IND#112603) in children with relapsed or refractory solid tumors: A Children’s Oncology Group study.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 2627-2627 ◽  
Author(s):  
James I. Geller ◽  
John Peter Perentesis ◽  
Charlotte H. Ahern ◽  
Rachel A. Kudgus ◽  
Elizabeth Fox ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Phase 1 ◽  
Oncology Group ◽  
Phase 1 Study ◽  
Oncology Group Study ◽  
Arq 197 ◽  
Met Inhibitor

Phase 1 Study of Paclitaxel Administered Twice Weekly to Children With Refractory Solid Tumors: A Pediatric Oncology Group Study

2003 ◽  
Vol 25 (7) ◽  
pp. 539-542 ◽  
Author(s):  
Robert J. Hayashi ◽  
Susan Blaney ◽  
Jim Sullivan ◽  
Steve Weitman ◽  
Teresa Vietti ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Pediatric Oncology ◽  
Phase 1 ◽  
Oncology Group ◽  
Phase 1 Study ◽  
Oncology Group Study ◽  
Pediatric Oncology Group

scholarly journals A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group

2018 ◽  
Vol 65 (8) ◽  
pp. e27077 ◽  
Author(s):  
Meredith K. Chuk ◽  
Brigitte C. Widemann ◽  
Charles G. Minard ◽  
Xiaowei Liu ◽  
AeRang Kim ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Solid Tumors ◽  
Phase 1 ◽  
Cns Tumors ◽  
Oncology Group ◽  
Phase 1 Study
Sign in / Sign up

Export Citation Format

Share Document